Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Platinum-resistant Ovarian Cancer
Clinical trial register · United States · industry-sponsored

Platinum-resistant Ovarian Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 8 Florida 6 New York 6 Michigan 5 Louisiana 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Platinum-resistant Ovarian Cancer trials in the USA

14 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Recruiting
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Active, closed
Novita Pharmaceuticals, Inc.
Phase 2/3
380
Arizona, Louisiana, New Mexico, Pennsylvania, Utah, Wisconsin
2025-12-29
Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
Michigan, Minnesota, New York, Texas
2025-06-16
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
MacroGenics
Phase 2
80
California, Louisiana, Michigan, Pennsylvania, Texas, Wisconsin
2025-05-01
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Active, closed
Genmab
Phase 3
584
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Recruiting
Genelux Corporation
Phase 3
186
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Michigan
2022-08-31
Active, closed
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
TILT Biotherapeutics Ltd.
Phase 1/2
29
Minnesota, New York
2022-05-17
Active, closed
Ascendis Pharma Oncology Division A/S
Phase 1/2
320
California, Illinois, Kentucky, Massachusetts, New Jersey, New York, North Carolina, Ohio
2022-01-11
Active, closed
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
NCT03949283Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Cordgenics, LLC
Phase 3
150
California, Florida, Louisiana, Ohio, Oklahoma, Pennsylvania, West Virginia
2019-07-26
Active, closed
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
NCT03319628Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Mersana Therapeutics
Phase 1/2
523
Oklahoma
2017-12-12
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/platinum-resistant-ovarian-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies listing the condition Platinum-resistant Ovarian Cancer.

How many Platinum-resistant Ovarian Cancer trials are recruiting in the US?

8 of the 14 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Platinum-resistant Ovarian Cancer), 14 studies
PhaseStudiesRecruitingShare
Phase 15535.7%
Phase 1/23021.4%
Phase 33121.4%
Phase 22214.3%
Phase 2/3107.1%

Most active sponsors

Lead sponsors with the most studies (Platinum-resistant Ovarian Cancer)
Lead sponsorStudiesRecruiting
Ascendis Pharma Oncology Division A/S10
Context Therapeutics Inc.11
Cordgenics, LLC10
Genelux Corporation11
Genmab10
ImmunityBio, Inc.11
MacroGenics11
Mersana Therapeutics10
NextCure, Inc.11
Novita Pharmaceuticals, Inc.10

Top states

Top states (Platinum-resistant Ovarian Cancer), by number of studies with a site there
StateStudies
California8
Florida6
New York6
Michigan5
Louisiana4
Massachusetts4
Arizona3
Arkansas3
Georgia3
Minnesota3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.